CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to a wide range of cancer antigens. We are leveraging this platform to advance a pipeline of potent and selective TCE therapeutics targeting intracellular and surface tumor antigens. With a team of proven drug development experts and backed by leading cross-Atlantic investors, we are working to empower patients’ own immune systems to eliminate tumors.
-
Branche
-
Biotechnologieforschung
-
Größe
-
51–200 Beschäftigte
-
Hauptsitz
-
Horgen, Zurich
-
Art
-
Privatunternehmen
-
Gegründet
-
2017
-
Spezialgebiete
-
Antibody fragments, Ophthalmology, Immuno-oncology, Biotechnology, Drug development, Entrepreneurship, Team culture, Targeted immuno-therapies, Oncology und Cancer